Onasemnogene abeparvovec is an adeno-associated virus, vector-based gene therapy indicated in patients less than 2 years of age who have SMA and bi-allelic mutations in the SMN1 gene [11,12]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.